What is the primary purpose of this merger between Pfizer and Allergan?

The primary purpose of the merger is to combine Pfizer's innovative medicines business with Allergan's diversified product portfolio, creating a leading global pharmaceutical company. A key driver for the transaction is the tax inversion aspect, which aims to establish the combined entity as an Irish-domiciled company for tax purposes, potentially lowering Pfizer's corporate tax rate.

How will Pfizer shareholders be compensated in this merger?

Pfizer shareholders will have the option to elect to receive either Allergan ordinary shares or cash for their Pfizer common stock. However, the total amount of cash distributed will be subject to proration, ensuring it falls within a specified range of $6 billion to $12 billion. Shareholders who do not make an election will receive the share consideration.

What are the key conditions required for this merger to be completed?

The merger is subject to numerous closing conditions, including the approval of the merger agreement by Pfizer shareholders and the approval of necessary corporate actions by Allergan shareholders. Additionally, regulatory approvals, such as those under the Hart-Scott-Rodino Antitrust Improvements Act, are required. The transaction also depends on the successful completion of Allergan's prior agreement to be acquired by Teva Pharmaceutical Industries Ltd.

What is the expected governance structure of the combined company?

Upon completion of the merger, the combined company, to be named Pfizer plc, will have a 15-member Board of Directors. This board will comprise eleven directors from Pfizer's existing board and four from Allergan's board. Key leadership roles will be filled by executives from both companies, with Pfizer's CEO expected to serve as Chairman and CEO of the combined entity, and Allergan's CEO as President and COO.

PFE 8-K: Leadership Changes & Material Agreements

Summary

Pfizer Inc. (PFE) filed an 8-K on November 23, 2015, to announce a significant definitive agreement to merge with Allergan plc. This transaction, structured as a "tax inversion" merger, would result in Pfizer becoming a subsidiary of Allergan, with the combined entity to be renamed Pfizer plc and headquartered in Ireland for tax purposes. The merger aims to create a global leader in the pharmaceutical industry, combining Pfizer's innovative medicines with Allergan's diversified portfolio. The deal's consideration structure allows Pfizer shareholders to elect either Allergan ordinary shares or a cash payment, subject to proration to manage the aggregate cash component within a specified range ($6 billion to $12 billion). The filing details the terms of the Merger Agreement, including closing conditions such as shareholder approvals from both Pfizer and Allergan, regulatory clearances (including HSR Act), and the successful completion of Allergan's previously announced acquisition of Allergan by Teva Pharmaceutical Industries Ltd. It also outlines the governance of the combined company, with a proposed 15-member board and leadership roles for key executives from both companies. The agreement includes provisions for termination fees under specific circumstances, with the potential for substantial financial penalties for either party if the deal is not completed as planned.

Key Highlights

1Pfizer Inc. entered into a definitive Agreement and Plan of Merger with Allergan plc, effective November 22, 2015.
2The transaction is structured as a merger of Allergan's subsidiary with Pfizer, making Pfizer a subsidiary of Allergan, with the combined entity to be named Pfizer plc and based in Ireland for tax purposes.
3Pfizer shareholders will receive either Allergan ordinary shares or cash, with elections subject to proration to maintain aggregate cash consideration between $6 billion and $12 billion.
4Completion of the merger is contingent on several conditions, including approvals from both Pfizer and Allergan shareholders, regulatory clearances, and the successful closing of Allergan's Teva transaction.
5The combined company's board will have 15 directors, with leadership roles designated for key executives from both Pfizer and Allergan.
6The merger agreement includes provisions for termination fees, with amounts varying based on the reasons for termination, including a potential $3.5 billion fee under certain circumstances.
7Executive retention awards of $1 million each were approved for Albert Bourla, Mikael Dolsten, Geno Germano, and John Young, contingent on their continued employment post-merger.

PFIZER INC 8-K Report, Material Agreement (Nov 23, 2015)

Summary

Key Highlights

Frequently Asked Questions